Medication info

Abipre Tablet 10/40 Milligrams

Prescription medicationTabletOralExpired
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Taeguk Pharmaceutical Co., Ltd.
Appearance
Reddish-brown round film-coated tablet
Packaging
30 tablets (10 tablets/PTP×3)
Approval status
Expired

MFDS item code 201907079 · Approved 2019.10.04

This product's status changed to Expired on 2024.10.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the dose be taken at the same time each day (e.g., in the morning). Before starting this drug, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This drug is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose with close monitoring of their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This drug should not be administered to patients with severe hepatic impairment. (See Precautions for Use, 2. Patients in Whom the Drug Must Not Be Administered.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
∘Pediatric patients: The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Taeguk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used for the treatment of essential hypertension in cases where blood pressure is not sufficiently controlled by monotherapy with amlodipine or olmesartan medoxomil. It helps to lower blood pressure and reduce the risk of cardiovascular diseases. It contributes to reducing the likelihood of complications from hypertension and improving overall heart health. Therefore, it is a suitable treatment option for patients with difficult-to-control blood pressure.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the dose be taken at the same time each day (e.g., in the morning). Before starting this drug, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This drug is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose with close monitoring of their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This drug should not be administered to patients with severe hepatic impairment. (See Precautions for Use, 2. Patients in Whom the Drug Must Not Be Administered.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

∘Pediatric patients: The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn when taken during the second and third trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. Patients who are allergic to the active ingredients or similar class drugs, pregnant women, breastfeeding women, patients with severe liver or aortic valve disease, patients with biliary obstruction, patients undergoing kidney dialysis, patients in shock, specific diabetic patients, and patients with severely impaired kidney function should not use this medication. It should be used with caution in patients with dehydration or low sodium levels, as hypotension may occur, and should be carefully administered to patients at risk of rapid blood pressure drop due to vasodilation, patients with coronary artery disease, patients with congestive heart failure, patients with weakened kidney function, and patients with impaired liver function. During use, side effects such as dizziness, headache, drowsiness, lowered blood pressure, nausea, vomiting, rash, and swelling may occur, so if symptoms are severe, consult a healthcare professional immediately. Although different from beta-blockers, this medication may interact with other blood pressure medications or specific drugs, so all medications being taken should be disclosed to the physician. During pregnancy, it may pose a risk to the fetus, so it is recommended to use safer alternative medications if planning to become pregnant or if already pregnant. If breastfeeding, as this medication can be transferred through breast milk and affect the baby, its use should be considered carefully. It is advisable not to use in children under 18 years of age, as safety and efficacy have not been established. Elderly patients may have reduced kidney and liver function, so it is recommended to start with a low dose and carefully monitor their condition. In case of overdose, severe hypotension and impaired heart function may occur, requiring immediate medical attention and continuous monitoring of blood pressure and heart status. This medication should be kept out of reach of children and stored in a cool place, avoiding direct sunlight and moisture.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensation diminution
  • syncope
Show 84 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • back pain
  • frequency of urination
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • weakness
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • rhinorrhea
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • herpes zoster
  • diplopia
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute renal failure
  • alopecia
  • itching
  • autoimmune hepatitis
  • angioedema
  • rhabdomyolysis
  • elevated serum creatinine
  • hyperkalemia
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is also best to store it at room temperature between 1°C and 30°C, avoiding extremely hot or cold places.

Appearance and packaging

Appearance

Reddish-brown round film-coated tablet

Package unit

30 tablets (10 tablets/PTP×3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.